Spruce Biosciences IncSPRB
Price$44.77

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0-100.0% YoYTTM through 30 Jun 2026
Net Income -$39MTTM through 30 Jun 2026
Free Cash Flow -$42.7MTTM through 30 Jun 2026

Margins

Current

Returns

-46.5%ROE
-37.9%ROA

Balance Sheet Health

Debt / Equity0.08x
Current Ratio9.23x
Net Debt-$48.9Mnet cash position
Cash & Equivalents$96.3M

Quality Metrics

Altman Z-Score0.06
Piotroski F-Score3 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $0
Diluted EPS-$38.43TTM
'21'22'23'24'25
FY2025: $-50.83

Dividend

No dividend

Capital Allocation

R&D Spend$28.9M

Segment Performance

SegmentRevenueYoYOutlook
Biopharmaceutical Development$0
View details

BLA submission for TA-ERT planned for the fourth quarter of 2026

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.